---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139409"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:10:56.774350+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics Q1 net loss $68.2M; VRDN-001 chronic TED data expected June/July 2023

## Summary
- Net loss of $68.2M for Q1 2023 vs. $25.7M in Q1 2022; R&D expenses $50.7M including $15M upfront to Enable Injections.
- Cash and short-term investments $373.9M at March 31, 2023, down from $424.6M at Dec 31, 2022; expected to fund into H2 2025.
- Topline data from VRDN-001 proof-of-concept study in chronic TED expected June/July 2023; THRIVE-2 Phase 3 initiation planned mid-2023.
- Lead subcutaneous (SC) program selection expected year-end 2023; IND for VRDN-003 to be filed Q2 2023.
- Appointed Tony Casciano as CCO, Thomas Ciulla as CDO, and other senior executives during Q1.

## SEC filing metadata
- accession: 0001193125-23-139409
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/d473560d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139409
- JSON: https://secwatch.observer/filing/0001193125-23-139409.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139409.txt

## Key facts
- Earnings Releases
  Viridian Therapeutics, Inc.\DE reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.